Cargando…

Effect of Paclitaxel Combined with Doxorubicin Hydrochloride Liposome Injection in the Treatment of Osteosarcoma and MRI Changes before and after Treatment

OBJECTIVE: The aim of this study is to investigate the effect of paclitaxel combined with doxorubicin hydrochloride liposome injection (DHLI) in the treatment of osteosarcoma and the MRI changes before and after treatment. METHODS: A total of 108 osteosarcoma patients treated in our hospital (Januar...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Ning, Wang, Dongmei, Li, Xiaobao, Xue, Minghua, Zheng, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356788/
https://www.ncbi.nlm.nih.gov/pubmed/35942377
http://dx.doi.org/10.1155/2022/5651793
_version_ 1784763594289709056
author Tian, Ning
Wang, Dongmei
Li, Xiaobao
Xue, Minghua
Zheng, Bo
author_facet Tian, Ning
Wang, Dongmei
Li, Xiaobao
Xue, Minghua
Zheng, Bo
author_sort Tian, Ning
collection PubMed
description OBJECTIVE: The aim of this study is to investigate the effect of paclitaxel combined with doxorubicin hydrochloride liposome injection (DHLI) in the treatment of osteosarcoma and the MRI changes before and after treatment. METHODS: A total of 108 osteosarcoma patients treated in our hospital (January 2020–April 2022) were selected to carry out a single-center retrospective study. Among them, 54 patients receiving the combination chemotherapy (MDT) with high-dose methotrexate, ifosfamide, cisplatin, and ADM were selected as the control group (COG), while 54 patients receiving MDT with high-dose methotrexate, ifosfamide, cisplatin, paclitaxel, and DHLI were chosen as the study group (STG). The COG and STG had the same dose intensity and chemotherapy cycles, and clinical and MRI evaluations were performed after treatment. RESULTS: The evaluation of postoperative clinical efficacy showed that the disease control rate (DCR) of the STG was markedly higher than that of the COG (P < 0.05). The incidence of cardiac toxicity was remarkably lower in the STG than that in the COG (P < 0.05), with no between-group differences in the incidence of fever, abnormal liver function, myelosuppression, stomatitis, and alopecia (P > 0.05). Obvious differences were found in the semiquantitative parameters of MRI in the STG before and after chemotherapy (P < 0.05) and were also found in the SI(max), TTP, SEE, PPE, WOR, and R values in the COG before and after chemotherapy (P < 0.05). After chemotherapy, statistical differences were observed in the semiquantitative parameters of MRI between the two groups, with lower parameters such as Slope, SI(max), SEE, and R values and higher parameters such as TTP, PPE, and WOR values in the STG than those in the COG (P < 0.05). CONCLUSION: Paclitaxel combined with DHLI has definite efficacy in osteosarcoma chemotherapy, which is conducive to narrowing the lesion, controlling the disease, and reducing the occurrence of cardiac-related risk events. In addition, the semiquantitative parameters of dynamic contrast-enhanced MRI (DCE-MRI) have a high predictive value for the efficacy of chemotherapy, which can reflect the degree of tumor necrosis and contribute to a timely and objective assessment of the efficacy of osteosarcoma chemotherapy.
format Online
Article
Text
id pubmed-9356788
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-93567882022-08-07 Effect of Paclitaxel Combined with Doxorubicin Hydrochloride Liposome Injection in the Treatment of Osteosarcoma and MRI Changes before and after Treatment Tian, Ning Wang, Dongmei Li, Xiaobao Xue, Minghua Zheng, Bo Evid Based Complement Alternat Med Research Article OBJECTIVE: The aim of this study is to investigate the effect of paclitaxel combined with doxorubicin hydrochloride liposome injection (DHLI) in the treatment of osteosarcoma and the MRI changes before and after treatment. METHODS: A total of 108 osteosarcoma patients treated in our hospital (January 2020–April 2022) were selected to carry out a single-center retrospective study. Among them, 54 patients receiving the combination chemotherapy (MDT) with high-dose methotrexate, ifosfamide, cisplatin, and ADM were selected as the control group (COG), while 54 patients receiving MDT with high-dose methotrexate, ifosfamide, cisplatin, paclitaxel, and DHLI were chosen as the study group (STG). The COG and STG had the same dose intensity and chemotherapy cycles, and clinical and MRI evaluations were performed after treatment. RESULTS: The evaluation of postoperative clinical efficacy showed that the disease control rate (DCR) of the STG was markedly higher than that of the COG (P < 0.05). The incidence of cardiac toxicity was remarkably lower in the STG than that in the COG (P < 0.05), with no between-group differences in the incidence of fever, abnormal liver function, myelosuppression, stomatitis, and alopecia (P > 0.05). Obvious differences were found in the semiquantitative parameters of MRI in the STG before and after chemotherapy (P < 0.05) and were also found in the SI(max), TTP, SEE, PPE, WOR, and R values in the COG before and after chemotherapy (P < 0.05). After chemotherapy, statistical differences were observed in the semiquantitative parameters of MRI between the two groups, with lower parameters such as Slope, SI(max), SEE, and R values and higher parameters such as TTP, PPE, and WOR values in the STG than those in the COG (P < 0.05). CONCLUSION: Paclitaxel combined with DHLI has definite efficacy in osteosarcoma chemotherapy, which is conducive to narrowing the lesion, controlling the disease, and reducing the occurrence of cardiac-related risk events. In addition, the semiquantitative parameters of dynamic contrast-enhanced MRI (DCE-MRI) have a high predictive value for the efficacy of chemotherapy, which can reflect the degree of tumor necrosis and contribute to a timely and objective assessment of the efficacy of osteosarcoma chemotherapy. Hindawi 2022-07-30 /pmc/articles/PMC9356788/ /pubmed/35942377 http://dx.doi.org/10.1155/2022/5651793 Text en Copyright © 2022 Ning Tian et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Tian, Ning
Wang, Dongmei
Li, Xiaobao
Xue, Minghua
Zheng, Bo
Effect of Paclitaxel Combined with Doxorubicin Hydrochloride Liposome Injection in the Treatment of Osteosarcoma and MRI Changes before and after Treatment
title Effect of Paclitaxel Combined with Doxorubicin Hydrochloride Liposome Injection in the Treatment of Osteosarcoma and MRI Changes before and after Treatment
title_full Effect of Paclitaxel Combined with Doxorubicin Hydrochloride Liposome Injection in the Treatment of Osteosarcoma and MRI Changes before and after Treatment
title_fullStr Effect of Paclitaxel Combined with Doxorubicin Hydrochloride Liposome Injection in the Treatment of Osteosarcoma and MRI Changes before and after Treatment
title_full_unstemmed Effect of Paclitaxel Combined with Doxorubicin Hydrochloride Liposome Injection in the Treatment of Osteosarcoma and MRI Changes before and after Treatment
title_short Effect of Paclitaxel Combined with Doxorubicin Hydrochloride Liposome Injection in the Treatment of Osteosarcoma and MRI Changes before and after Treatment
title_sort effect of paclitaxel combined with doxorubicin hydrochloride liposome injection in the treatment of osteosarcoma and mri changes before and after treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356788/
https://www.ncbi.nlm.nih.gov/pubmed/35942377
http://dx.doi.org/10.1155/2022/5651793
work_keys_str_mv AT tianning effectofpaclitaxelcombinedwithdoxorubicinhydrochlorideliposomeinjectioninthetreatmentofosteosarcomaandmrichangesbeforeandaftertreatment
AT wangdongmei effectofpaclitaxelcombinedwithdoxorubicinhydrochlorideliposomeinjectioninthetreatmentofosteosarcomaandmrichangesbeforeandaftertreatment
AT lixiaobao effectofpaclitaxelcombinedwithdoxorubicinhydrochlorideliposomeinjectioninthetreatmentofosteosarcomaandmrichangesbeforeandaftertreatment
AT xueminghua effectofpaclitaxelcombinedwithdoxorubicinhydrochlorideliposomeinjectioninthetreatmentofosteosarcomaandmrichangesbeforeandaftertreatment
AT zhengbo effectofpaclitaxelcombinedwithdoxorubicinhydrochlorideliposomeinjectioninthetreatmentofosteosarcomaandmrichangesbeforeandaftertreatment